647 filings
Page 25 of 33
4
wdx8q6 j3a
3 Oct 16
Cerecor / Magnus Persson ownership change
12:00am
4
bflqg1383sqwxw
3 Oct 16
Cerecor / Phil Gutry ownership change
12:00am
4
q13rg v1rnepom
3 Oct 16
Cerecor / EUGENE A BAUER ownership change
12:00am
4
km9isll sgf4kjdql76
3 Oct 16
Cerecor / Thomas H Aasen ownership change
12:00am
424B3
pvmwpi3e0jb
3 Oct 16
Prospectus supplement
12:00am
EFFECT
2atwtcy glz9
28 Sep 16
Notice of effectiveness
12:00am
CORRESP
avmuwt
26 Sep 16
Correspondence with SEC
12:00am
424B3
0wf u1yfmuki707120w
26 Sep 16
Prospectus supplement
12:00am
8-K
d7ql609pxneb 7t73bad
26 Sep 16
Cerecor Announces Acquisition of TARP-γ8-AMPA Receptor Antagonist (CERC-611) from Lilly
12:00am
UPLOAD
nwjsexwr
23 Sep 16
Letter from SEC
12:00am
8-K
hx1koi5bftsw07
21 Sep 16
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
12:00am
424B3
off1p18a
21 Sep 16
Prospectus supplement
12:00am
D
8029fllw oi962kt5
16 Sep 16
$15M in equity, sold $1M, 1 investor
12:00am
8-K
zunfgxtk4tma8rehfdkd
12 Sep 16
Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
424B3
vzvagg8hl
12 Sep 16
Prospectus supplement
12:00am
424B3
j3weubm
6 Sep 16
Prospectus supplement
12:00am
8-K
2xi6hde1u09
6 Sep 16
Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
12:00am
8-K
18ae71 ppisadc
29 Aug 16
Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
12:00am
424B3
6ta fkcag36qd99t27jl
29 Aug 16
Prospectus supplement
12:00am